The Indian Pharma Industry is expected to reach $130 billion by 2030 from existing $49.78 billion as of 2023, with a CAGR of 14.7 percent. About 30 percent of Indian Pharmaceutical exports are accounted by US alone.
On 3 April 2025, the US administration announced that it would exempt India’s pharma industry from reciprocal tariffs. In this article, we would look at one company which will benefit from recent developments.
With a market capitalization of Rs 677 crore, the shares of Medicamen Biotech Ltd made a 52-week high of Rs 630 per share, down by 15 percent from its current market price of Rs 533.30 per share.
About the announcement
On 3 April 2025, the company announced that it had signed a contract for Contract Development and Manufacturing Organization (CDMO) with XGX Pharma (European company), where Medicamen Biotech will develop 6 products and will do the manufacturing of these products for XGX Pharma. XGX will hold the market authorisation for these products.
XGX Pharma works with partners to enhance its market reach and has agreements with companies like Medicamen Biotech to manufacture and develop its products. The company holds the market authorizations for these products in various regions.
Financials
Medicamen Biotech Ltd reported a revenue of Rs 45.14 crore in Q3 FY25, down by 2.9 percent, from its Q3 FY24 revenue of Rs 46.50 crore. It posted a net profit of Rs 2.92 crore in Q3 FY25, up by 43.8 percent, from its Q3 FY24 net profit of Rs 2.03 crores and up by 220 percent from its Q2 FY25 net profit of Rs 0.91 crores.
About the Company
Medicamen Biotech Limited is a pharmaceutical company that researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally.
The company offers drugs in various forms such as tablets, capsules, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarial, vitamins and supplements, other generics, and pain management.